Top-News

Pavmed Aktie News

Aktie
WKN:  A3E2MX ISIN:  US70387R4039 US-Symbol:  PAVM Branche:  Gesundheitswesen: Ausstattung u. Produkte Land:  USA
0,329 $
-0,012 $
-3,52%
0,28255 € 05.12.25
Depot/Watchlist
Marktkapitalisierung *
2,22 Mio. €
Streubesitz
-
KGV
-
Index-Zuordnung
-

Pavmed News

30.07.25 - PR Newswire
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025 PR Newswire
16.07.25 - PR Newswire
MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test
MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test PR Newswire
24.06.25 - PR Newswire
PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing
PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing PR Newswire
18.06.25 - PR Newswire
Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test
Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test PR Newswire
03.06.25 - PR Newswire
PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove ...
27.05.25 - PR Newswire
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes PR Newswire
15.05.25 - PR Newswire
PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results
PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results PR Newswire
14.05.25 - PR Newswire
Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results
Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results PR Newswire
01.05.25 - PR Newswire
PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025
PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025 PR Newswire
30.04.25 - PR Newswire
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025 PR Newswire
24.04.25 - PR Newswire
NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD
NCI-​Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD PR Newswire
11.04.25 - PR Newswire
Lucid Diagnostics Announces Closing of Public Offering of Common Stock
Lucid Diagnostics Announces Closing of Public Offering of Common Stock PR Newswire
09.04.25 - PR Newswire
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock PR Newswire
09.04.25 - PR Newswire
Lucid Diagnostics Announces Proposed Public Offering of Common Stock
Lucid Diagnostics Announces Proposed Public Offering of Common Stock PR Newswire
03.04.25 - PR Newswire
Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference PR Newswire
27.03.25 - PR Newswire
Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology
Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology PR Newswire
24.03.25 - PR Newswire
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results PR Newswire
20.03.25 - PR Newswire
Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening
Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening PR Newswire
18.03.25 - PR Newswire
Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-​Reviewed Publication PR Newswire
13.03.25 - PR Newswire
Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test
Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test PR Newswire

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »